Prevalence of HCV resistance‐associated substitutions among treatment‐failure patients receiving direct‐acting antiviral agents-Reference-Cited by-同舟云学术

Prevalence of HCV resistance‐associated substitutions among treatment‐failure patients receiving direct‐acting antiviral agents

Published:2020-02-27 Issue:6 Volume:27 Page:585-592
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Liu Zhenqiu¹²³^ORCID,Mao Xianhua¹³,Yu Kangkang⁴,Suo Chen³⁵⁶,Jin Li¹²³,Zhang Tiejun³⁵⁶,Chen Xingdong¹²³

Affiliation:

1. State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development School of Life Sciences Fudan University Shanghai China

2. Human Phenome Institute Fudan University Shanghai China

3. Fudan University Taizhou Institute of Health Sciences Taizhou China

4. Department of Infectious Diseases Huashan Hospital Fudan University Shanghai China

5. Department of Epidemiology School of Public Health Fudan University Shanghai China

6. Ministry of Education Key Laboratory of Public Health Safety (Fudan University) Shanghai China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13270

Reference33 articles.

1. Global epidemiology and burden of HCV infection and HCV-related disease

2. Natural history of hepatitis C

3. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013

4. Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences;Pathogens;2024-08-09

2. CRISPR/Cas9 as a New Antiviral Strategy for Treating Hepatitis Viral Infections;International Journal of Molecular Sciences;2023-12-26

3. Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis;Nature Communications;2023-11-17

4. Real-World Therapeutic Outcomes of Direct-Acting Antiviral Regimens and Formidable Challenges;Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives;2023-01

5. Efficacy and safety of direct‐acting antiviral therapies and baseline predictors for treatment outcomes in hepatitis C patients: A multicenter, real‐world study in Guangdong, China;Journal of Medical Virology;2022-05-31